Oral lesions and associated factors in breast cancer survivors
ConclusionApproximately 1/4 of the BC survivors exhibited OL, which were associated with tooth loss and xerostomia. These findings could assist in the establishment of oral health strategies for women with BC. (Source: Dental Technology Blog)
Source: Dental Technology Blog - August 14, 2019 Category: Dentistry Source Type: news
Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer
Cancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2019 Category: Cancer & Oncology Authors: Marleen Meyers, MD Source Type: news
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to endocrine therapy alone in pre- and perimenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer[1]. (Source: World Pharma News)
Source: World Pharma News - June 3, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Study: Genetic information can encourage women to accept preventive cancer treatment
CHICAGO ?-- Studies show that the risk of breast cancer can be reduced by half through the use of a five-year course of tamoxifen or raloxifene, and also by aromatase inhibitors. Nevertheless, women at high risk of breast cancer have a low acceptance of preventive medicine. A new study by Mayo Clinic and collaborators at [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - June 2, 2019 Category: Hospital Management Source Type: news
Riskreducing medications for primary breast cancer: a network metaanalysis
This Cochrane Review of 6 studies (n=50,927 on 1 cancer prevention agent (CPA:tamoxifen/raloxifene/exemestane/anastrozole] or placebo) found for women at above ‐average risk of developing breast cancer, CPAs can reduce incidence of this disease. Aromatase inhibitors appear to be more effective. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 29, 2019 Category: Consumer Health News Source Type: news
Value of Androgen Receptor Expression in ER+ Breast Cancer Value of Androgen Receptor Expression in ER+ Breast Cancer
Does androgen receptor expression predict response to tamoxifen in women with ER+ breast cancers?Breast Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 10, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
' Outside the Box': Tamoxifen for Bladder Cancer'Outside the Box': Tamoxifen for Bladder Cancer
Widely used in the treatment of breast cancer because of its estrogen-blocking activity, tamoxifen has now been tested for the first time in bladder cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 7, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Nolvadex (Tamoxifen Citrate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 30, 2019 Category: Drugs & Pharmacology Source Type: news
Promising Strategy Identifies Triple-Negative Breast Cancers That Might Respond to Tamoxifen Promising Strategy Identifies Triple-Negative Breast Cancers That Might Respond to Tamoxifen
Triple-negative breast cancer (TNBC) tumors with estrogen receptor-beta and a mutated p53 tumor suppressor might be responsive to tamoxifen, a series of preclinical studies suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Medical News Today: Breast cancer: Reducing this amino acid could make drugs more effective
New research in cell cultures and mice reveals a surprising link between the essential amino acid leucine and resistance to tamoxifen in breast cancer. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 18, 2019 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Diet high in leucine may fuel breast cancer's drug resistance
(Beth Israel Deaconess Medical Center) A team led by Senthil Muthuswamy, PhD, at the Cancer Center at Beth Israel Deaconess Medical Center, has discovered an unexpected relationship between levels of the amino acid leucine (found in beef, chicken, pork and fish and other foods) and the development of tamoxifen resistance in ER+ breast cancer. These findings reveal a potential new strategy for overcoming resistance to endocrine drugs in ER+ breast cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 17, 2019 Category: Cancer & Oncology Source Type: news
Fulvestrant-anastrozole Combo Improves Survival in Metastatic Breast Cancer Fulvestrant-anastrozole Combo Improves Survival in Metastatic Breast Cancer
More than six years after a study showed that women with hormone-receptor-positive metastatic breast cancer benefit from a combination of anastrozole and fulvestrant, extended results show the trend has become even more pronounced, but mostly for women not previously exposed to tamoxifen.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Role of Chemopreventive Agents in Women at Increased Risk for Breast Cancer
Cancer Network spoke with Charles Shapiro, MD, about the USPSTF ' s stance on use of tamoxifen, raloxifene, and aromatase inhibitors to prevent breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 18, 2019 Category: Cancer & Oncology Authors: Charles Shapiro, MD Source Type: news
'Molecular wiring of tumour' predicts breast cancer relapse
New research could lead the way to molecular based treatment and follow-up plans Related items fromOnMedica Thousands of women with breast cancer may be spared chemotherapy Benefit of Herceptin in more breast cancer cases MRI in breast cancer fails to cut reoperation rate Mortality higher if using paroxetine and tamoxifen Physical problems after breast cancer limit survival (Source: OnMedica Latest News)
Source: OnMedica Latest News - March 13, 2019 Category: UK Health Source Type: news
High Street supplements marketed for heart health and energy could combat infertility
A study by the University of Aberdeen also found that the breast-cancer drug tamoxifen - which blocks oestrogen from fueling a tumour's growth - has a positive effect on a man's swimmers. (Source: the Mail online | Health)
Source: the Mail online | Health - February 14, 2019 Category: Consumer Health News Source Type: news
